- According to estimates from 7 analysts, Adaptive Biotechnologies Corporation stock's average price target has risen from $22.29 to $24, with forecasts ranging from $20 to $28 per share
- Based on the Jul. 29 closing price, the updated target implies approximately 6% potential upside
- Consensus rating remains at “Buy” across 8 covering analysts, with 7 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Adaptive Biotechnologies Corporation on the , and track all previous and future analyst recommendations for Adaptive Biotechnologies Corporation in the dedicated .
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.